Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery.
Acute kidney injury
Antineoplastic agents
Epidemiology
Multiple myeloma
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
11
04
2024
accepted:
16
08
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Kidney disease is a common complication of multiple myeloma (MM) and a risk factor for increased morbimortality. In this retrospective cohort study based on medical records, we analyzed the kidney function of patients with renal disease related to MM during the first year of treatment. All patients included were consecutively admitted to the outpatient services of two hospitals between January 2009 and January 2019 and met the diagnostic criteria for MM regardless of the reason for seeking medical help. We excluded patients who had kidney disease or who were on dialysis before MM diagnosis. We investigated the factors associated with renal function recovery using multivariate analysis. We evaluated 167 patients (median age of 66 ± 11.49 years). Almost half of the patients had arterial hypertension (76; 45.5%). The majority had International Staging System (ISS) grades 3 (73; 43.7%) or 2 (60; 35.9%). Seventy-four (44%) patients had an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² at the time of MM diagnosis. Fifty-two patients (31%) underwent hematopoietic stem cell transplantation (HSCT). After 12 months, 4 (2.3%) patients needed dialysis, and 18 (10.7%) died. The factors associated with an eGFR < 60 ml/min/1.73 m² were anemia, hyperuricemia, 24-hour proteinuria > 1.0 g, and extramedullary plasmacytoma. However, only baseline renal function (eGFR > 60 ml/min/1.73 m
Identifiants
pubmed: 39390432
doi: 10.1186/s12882-024-03717-5
pii: 10.1186/s12882-024-03717-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
344Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
pubmed: 35020204
doi: 10.3322/caac.21708
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
pubmed: 25439696
doi: 10.1016/S1470-2045(14)70442-5
Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337–41.
pubmed: 17325894
doi: 10.1080/10428190601126602
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501–6.
pubmed: 20823456
pmcid: 3031400
doi: 10.1182/blood-2010-07-298760
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group Recommendations for the diagnosis and management of Myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–57.
pubmed: 26976420
doi: 10.1200/JCO.2015.65.0044
Katagiri D, Noiri E, Hinoshita F. Multiple myeloma and kidney disease. ScientificWorldJournal. 2013;2013:487285.
pubmed: 24288486
pmcid: 3826468
doi: 10.1155/2013/487285
Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. J Nephrol. 2019;32(2):189–98.
pubmed: 29730782
doi: 10.1007/s40620-018-0492-4
Bayraktar UD, Warsch S, Pereira D. High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. Am J Hematol. 2011;86(2):224–7.
pubmed: 21264915
doi: 10.1002/ajh.21922
Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546–9.
pubmed: 17488666
doi: 10.3324/haematol.10759
Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27(36):6086–93.
pubmed: 19858394
doi: 10.1200/JCO.2009.22.2232
Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423–9.
pubmed: 22763386
doi: 10.1038/leu.2012.182
Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635–41.
pubmed: 20823423
doi: 10.1200/JCO.2010.28.1238
Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84(3):223–8.
pubmed: 19930441
doi: 10.1111/j.1600-0609.2009.01385.x
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499–502.
pubmed: 26890495
doi: 10.1002/ajh.24335
Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transpl. 2004;33(8):823–8.
doi: 10.1038/sj.bmt.1704440
Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transpl. 2009;15(7):812–6.
doi: 10.1016/j.bbmt.2009.03.021
Tarragon B, Ye N, Gallagher M, Sen S, Portoles JM, Wang AY. Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis. Clin Kidney J. 2021;14(8):1894–900.
pubmed: 34345412
doi: 10.1093/ckj/sfaa220
Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282–8.
pubmed: 18385667
doi: 10.1038/ki.2008.108
Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364(24):2365–6.
pubmed: 21675906
doi: 10.1056/NEJMc1101834
Park S, Han B, Kim K, Kim SJ, Jang JH, Kim WS, et al. Renal insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. Anticancer Res. 2014;34(8):4299–306.
pubmed: 25075062
Antlanger M, Dust T, Reiter T, Bohm A, Lamm WW, Gornicec M, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018;18(1):1008.
pubmed: 30342509
pmcid: 6195957
doi: 10.1186/s12885-018-4926-0
Chen J, Liu H, Li L, Liu Z, Song J, Wang G, et al. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. J Clin Lab Anal. 2019;33(5):e22888.
pubmed: 31004381
pmcid: 6595344
doi: 10.1002/jcla.22888
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, et al. Renal impairment at diagnosis in Myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and related diseases Registry. Clin Lymphoma Myeloma Leuk. 2019;19(8):e415–24.
pubmed: 31208889
doi: 10.1016/j.clml.2019.05.010
Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79(8):1987–94.
pubmed: 1373333
doi: 10.1182/blood.V79.8.1987.1987
Means RT Jr., Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992;80(7):1639–47.
pubmed: 1391934
doi: 10.1182/blood.V80.7.1639.1639
Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82(4):648–53.
pubmed: 1482651
doi: 10.1111/j.1365-2141.1992.tb06939.x
Hare GM, Freedman J, David Mazer C. Review article: risks of anemia and related management strategies: can perioperative blood management improve patient safety? Can J Anaesth. 2013;60(2):168–75.
pubmed: 23354944
doi: 10.1007/s12630-012-9861-y
Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS ONE. 2013;8(2):e55870.
pubmed: 23457485
pmcid: 3573047
doi: 10.1371/journal.pone.0055870
Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transpl. 2013;28(9):2221–8.
doi: 10.1093/ndt/gft029
Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–8.
pubmed: 23235493
doi: 10.1159/000345509
Rabadi MM, Kuo MC, Ghaly T, Rabadi SM, Weber M, Goligorsky MS, et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Ren Physiol. 2012;302(6):F730–41.
doi: 10.1152/ajprenal.00520.2011
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75.
pubmed: 18192841
doi: 10.1097/HJH.0b013e3282f240bf
Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Ren Physiol. 2013;304(5):F471–80.
doi: 10.1152/ajprenal.00560.2012
Motwani SS, Herlitz L, Monga D, Jhaveri KD, Lam AQ. American Society of Nephrology Onco-Nephrology F. Paraprotein-related kidney disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol. 2016;11(12):2260–72.
pubmed: 27526706
pmcid: 5142064
doi: 10.2215/CJN.02980316
Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma–a demographic study of 1353 patients. The nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207–12.
pubmed: 7957804
doi: 10.1111/j.1600-0609.1994.tb00190.x
Jagosky MH, Usmani SZ. Extramedullary Disease in multiple myeloma. Curr Hematol Malig Rep. 2020;15(2):62–71.
pubmed: 32198576
doi: 10.1007/s11899-020-00568-3
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–7.
pubmed: 22689675
pmcid: 3487453
doi: 10.3324/haematol.2012.065698
Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15(5):286–91.
pubmed: 25640025
doi: 10.1016/j.clml.2014.12.013
Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–7.
pubmed: 29419433
pmcid: 5927971
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219–26.
pubmed: 16275935
doi: 10.1200/JCO.2005.03.2086
Chen X, Luo X, Zu Y, Issa HA, Li L, Ye H, et al. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. J Clin Lab Anal. 2020;34(9):e23416.
pubmed: 32710448
pmcid: 7521223
doi: 10.1002/jcla.23416
Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transpl. 2021;36(3):482–90.
doi: 10.1093/ndt/gfz211
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–9.
pubmed: 11564069
doi: 10.1046/j.1365-2141.2001.03033.x
Lazana I, Floro L, Christmas T, Shah S, Bramham K, Cuthill K, et al. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transpl. 2022;57(6):959–65.
doi: 10.1038/s41409-022-01657-y